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Abstract: Gene perturbation methods are commonly used in the study of gene and protein 
function. The authors of this paper recently developed a rapid protein inactivation technique 
utilizing tobacco etch virus (TEV)-derived protease. TEV protease recognizes the ENLYFQG 
(Glu-Asn-Leu-Tyr-Phe-Gln-Gly) amino acid sequence and specifically cleaves between Q and G. 
The authors developed antibodies that recognize the cleaved TEV (ENLYFQ) sequence, both 
in vitro and in vivo, but do not bind to uncleaved TEV (ENLYFQG). Using these antibodies, in 
situ protein cleavage was successfully detected. These antibodies used in combination with the 
TEV protease may be a useful complement to other perturbation methods.
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Introduction
The characterization of gene product function is an important challenge in the field 
of cell biology, especially since the completion of the Human Genome Project. 
Additionally, research into the causes of human disorders has revealed that defects 
in  intracellular membrane trafficking can cause serious diseases.1,2 Therefore, 
understanding how gene products are transported via membrane trafficking and how 
trafficking affects their function is crucial.
Ribonucleic acid (RNA) interference (RNAi) is a powerful technique used to 
disrupt a given messenger RNA using complementary double-stranded RNA, thereby 
reducing corresponding protein levels.3 This technique is applicable for cell-based 
assays and therefore has been widely used by researchers in the field of cell biology, 
including membrane trafficking. Although RNAi is useful, there are certain limita-
tions associated with its use. For example, the depletion of the Golgi matrix protein 
GM130 by RNAi has been described by three different groups and has resulted in 
contradictory phenotypes.4–6
According to published data and our experience, the depletion of Golgi-related 
 proteins by RNAi takes 72–96 hours,6–8 during which time the cells either die or 
 compensate by adjusting the expression levels of other genes. Therefore, any phenotype 
observed may not reflect the primary loss of function phenotype for the disrupted gene. 
To address these concerns, we developed a technique for the rapid inactivation of proteins 
that allows accurate observation of the primary effects of gene product perturbation.9
For rapid inactivation, we chose the tobacco etch virus (TEV)-derived protease 
(TEV protease). TEV protease is unique in its extremely precise cleavage specificity: 
it recognizes the ENLYFQG (Glu-Asn-Leu-Tyr-Phe-Gln-Gly) consensus sequence and 





cleaves between Q and G. Using nested polymerase chain 
reaction, a TEV protease recognition site was introduced into 
a cDNA (complementary deoxyribonucleic acid) expression 
construct. After transfection, the protein was treated with 
the TEV protease by microinjection, both in vitro and in 
situ. Since the TEV recognition sequence is not found in the 
human gene database, this method can be used to rapidly 
remove any protein from the cell.
Using this method, we had previously demonstrated that 
in situ cleavage of p115, a coat protein I vesicle-tethering 
protein, caused reduced cargo trafficking.9 However, we 
were unable to demonstrate direct protein cleavage in cells 
because of a lack of visualization tools. Here we raised 
anti-TEV (which recognizes only C-terminal ENLYFQ, 
not ENLYFQG or internal ENLYFQG) antibodies to detect 
the cleaved TEV sequence and were able to specifically 
detect in situ protein cleavage. Therefore, the use of these 
antibodies in combination with TEV protease can be a 




The antibodies used in this study are as follows: monoclonal 
anti-influenza hemagglutinin (anti-HA) (16B12, BAbCO, 
Richmond, CA), polyclonal anti-giantin,10 Alexa-conjugated 
secondary antibodies (Invitrogen, Carlsbad, CA), and horse-
radish peroxidase-conjugated secondary antibodies (Pierce, 
Rockford, IL). Anti-HA agarose was obtained from Sigma 
(St Louis, MO).
Production of anti-TEV antibodies
Polyclonal rabbit anti-TEV antibodies were raised using 
TEV-cleaved hexapeptide (ENLYFQ) as an antigen 
 (Figure 1A). A cysteine residue was added at its N-terminus 
for conjugation to keyhole limpet hemocyanin (KLH), 
and 6-aminohexanoic acid (Ahx) was used as a spacer 
 (Figure 1A). Peptide synthesis by Fmoc (fluorenylmethoxy-
carbonyl) solid phase synthesis, immunization using the 
KLH-conjugated peptide and Freund’s complete adjuvant, 
and a titer check by enzyme-linked immunosorbent assay 
(ELISA) were performed by Operon Biotechnologies 
(Tokyo, Japan). The first and second bleeds were col-
lected a week after the first and second immunizations, 
respectively. Immediately after the third immunization and 
bleed, exsanguination was performed. Pooled anti-sera were 
used in this study.
Plasmids and stable cell lines
The C-terminal TEV-cleaved sequence (ENLYFQ)-bearing 
p115 (Figure 1C) was generated by site-directed mutagenesis 
by introducing a stop codon between Q and G of the internal 
TEV-modified p115 (Figure 1B). The truncated p115 (1–886) 
and HeLa cells stably expressing the internal TEV-modified 
p115 were described previously.9 We modified green fluores-
cence protein (GFP)-tagged golgin84 used in the study by Satoh 
et al11 to insert the TEV cleavage site at the 300th amino acid 
of golgin-84 (Figure 4A). The internal TEV-modified golgin 84 
was expressed transiently by transfection in HeLa cells.9 The 
transient transfection was performed with Lipofectamine 
LTX (Invitrogen) following the manufacturer’s protocol.
Cell culture and microinjection
Cells were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum on 12-mm glass 
coverslips. Desalted TEV protease (∼4 U/µL, Invitrogen) 
together with Alexa-conjugated dextran (1 µg/µL) as an 
injection marker was injected into the cytoplasm. After the 
microinjection, the cells were incubated for 1.5–3.0 hours 
at 37°C and then processed for immunofluorescence. In 
typical experiments, 40–100 cells were injected.
immunoprecipitation (iP) and Western 
blotting9,11
Cell lysates were prepared with IP buffer (10 mM HEPES 
[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid]-KOH, 
pH 7.4, 100 mM KCl, 0.1 mM dithiothreitol [DTT], 2.5 mM 
MgCl
2
, 1% Triton X-100 and the protease inhibitor cocktail 
from Roche, Penzberg, Upper Bavaria, Germany). After 
incubation for 10 minutes on ice, the extract was clarified by 
centrifugation at 14,000 g for 20 minutes. For IP, the superna-
tants (∼100 µg protein) were incubated with anti-HA agarose 
(Sigma) or anti-GFP agarose (MBL, Woburn, MA) for 
30 minutes at 4°C. After washing three times with IP buffer, 
the beads were washed three times with TEV buffer (50 mM 
Tris-HCl [pH 8.0], 0.5 mM ethylenediaminetetraacetic acid, 
1 mM DTT). Proteins on the beads were then incubated with/
without TEV protease (5 U, Invitrogen) for 1 hour at 30°C. 
The samples were fractionated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis followed by Western 
blotting, with antibodies indicated in the figures.
Immunofluorescence microscopy9,11
Cells on coverslips wer e fixed with 3.7% formalin in 
phosphate buffered saline (PBS) for 15 minutes and per-
meabilized with 0.1% Triton X-100 in PBS for 5 minutes at 
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room temperature. The cells were blocked with 4% bovine 
serum albumin (BSA) in PBS for 15 minutes, and then 
incubated for 15 minutes with primary antibodies diluted 
in 4% BSA in PBS. The cells were washed three times 
with PBS, and incubated for 15 minutes with secondary 
antibodies conjugated to Alexa Fluor® Dyes (Invitrogen). 
After washing the cells, the coverslips were mounted on 
microscope slides and imaged using an FV1000 confocal 
microscope equipped with a 60 × oil objective (Olympus, 
Tokyo, Japan).
Results and discussion
Production of cleaved TEV  
(ENLYFQ)-specific antibodies
In general, sequence epitopes in proteins consist of 6–12 amino 
acids.12–14 Since the cleaved TEV (ENLYFQ) was a hexapep-
tide, a non-antigenic Ahx was used as a spacer (Figure 1A) 
to maximize the presentation of the antigen peptide. The 
titers were determined by ELISA (not shown). The first and 
second bleeds were collected a week after the first and second 
Figure 1 (A) The antigen peptide. Cysteine was added at the n-terminus for KLH conjugation. Ahx was used as a spacer. (B, C) Schematic models of modified p115 constructs 
used in this study. The TEV protease recognizes the heptapeptide sequence ENLYFQG and cleaves between Q and G with high specificity. This heptapeptide was inserted 
between amino acids 886 and 887 of bovine p115 (internal TEV-modified p115) (B). As a cleaved control, truncated p115 (1–886) followed by TEV-cleaved EnLYFQ sequence 
was constructed (C-terminal-cleaved TEV-bearing p115 (1–886)) (C). Both constructs were tagged with HA at their n-termini for detection. (D) Detection of in-vitro cleavage 
of internal TEV-modified p115. HeLa cells stably expressing the TEV-modified p115 with N-terminal HA tag were used. HA-tagged modified p115 was immunoprecipitated with 
anti-HA-agarose from cell lysates, and immunoreactive complexes were treated with or without the TEV protease for 30 minutes at 30°C and analyzed by Western blotting with 
anti-TEV (left panel) and anti-HA (right panel, to detect the N-termini) antibodies. The anti-TEV antibodies specifically recognized the cleaved protein but not the full-length protein. 
Abbreviations: Ahx, 6-aminohexanoic acid; EnLYFQG, Glu-Asn-Leu-Tyr-Phe-Gln-Gly; HA, hemagglutinin; KLH, keyhole limpet hemocyanin; TEV, tobacco etch virus.





Figure 2 Specificity of anti-TEV antibodies in immunofluorescence applications. HeLa cells transiently expressing the TEV-modified p115 with N-terminal HA tag 
(A–C) and C-terminal cleaved TEV-bearing p115 (D–F) were fixed and immunostained with anti-TEV (left panels, red) and anti-HA (middle panels, green) antibodies. 
The merged images with nuclear staining (blue) are shown on the right. Cells expressing HA-constructs are indicated with white arrows. The anti-TEV antibodies 
did not recognize uncleaved proteins in immunofluorescence applications. HeLa cells transiently expressing truncated p115 (1–886, G–I) and the C-terminal TEV-
cleaved p115 (1–886, J–L) were immunostained with anti-giantin (G, J; red, Golgi marker) and anti-HA (H, K; green) antibodies. The merged images with nuclear 
staining (blue) are shown on the right. The addition of EnLYFQ to the truncated p115 (1–886) interfered with its localization to the Golgi apparatus (white arrows). 
Abbreviations: EnLYFQG, Glu-Asn-Leu-Tyr-Phe-Gln-Gly; HA, hemagglutinin; TEV, tobacco etch virus; w/o, without.
immunizations, respectively. Immediately after the third 
immunization and bleed, exsanguination was performed. 
Pooled anti-sera were used in this study.
Detection of in vitro protein cleavage  
by anti-TEV antibodies
To test the specificity of the anti-TEV antibody, in vitro cleav-
age of the modified p115 was performed. The TEV-modified 
p115 was immunoisolated from HeLa cells stably expressing 
the modified p1159 via its N-terminal HA-tag by IP with 
anti-HA-agarose. Immunoreactive complexes were treated 
with or without the TEV protease, and analyzed by Western 
blotting with anti-TEV (Figure 1D, left panel) and anti-HA 
(Figure 1D, right panel) antibodies. HA staining revealed that 
the cleavage was incomplete, with approximately 35% of the 
modified p115 uncleaved in the condition tested. The anti-
TEV antibodies specifically recognized the cleaved protein 
but not full-length p115 (Figure 1D, left panel).
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Detection of in situ protein cleavage  
by anti-TEV antibodies
To test the specif icity of the anti-TEV antibody in 
immunofluorescence applications, the internal TEV-modified 
p115 (Figure 1B) and C-terminal TEV-cleaved ENLYFQ-
bearing truncated p115 (1–886) (Figure 1C) were expressed 
transiently, and cells were immunostained using anti-TEV 
and anti-HA antibodies. The latter was used to detect N-ter-
minal HA-tags. The anti-TEV antibodies did not recognize 
the internal TEV-modified p115 (Figures 2A–2C), whereas it 
did recognize the C-terminal TEV-cleaved ENLYFQ-bearing 
p115 (1–886) (Figures 2D–2F).
Since the authors of this paper noticed that the C-terminal 
TEV-cleaved ENLYFQ-bearing p115 (1–886) localized 
throughout the cells, they compared the subcellular localiza-
tion of this protein to that of p115 (1–886) without ENLYFQ. 
Both constructs were expressed transiently, and stained for 
giantin, a Golgi marker (Figures 2G and 2J), and HA to 
mark their N-termini (Figures 2H and 2K). The majority 
of the truncated p115 (1–886, without ENLYFQ) localized 
to the Golgi area marked by giantin (Figures 2G–2I), whereas 
the C-terminal TEV-cleaved ENLYFQ-bearing p115 did not 
(Figures 2J–2L). These data suggest that the addition of 
ENLYFQ may mask the binding site(s) in p115 (1–886) to 
the Golgi apparatus. These binding sites could be located in 
the head (1–651 for GBF1, Cog2, and Rab1 bindings), the 
first coiled-coil (652–701 for SNARE and Rab1 bindings), 
and/or the second coiled-coil (704–776 for Rab1 binding) 
domains of p115.15–19
Furthermore, in situ protein cleavage was performed 
by microinjecting the TEV protease into HeLa cells  stably 
expressing the internal TEV-modified p115. To mark 
the  protease-injected cells, Alexa-labeled dextran was 
 co- injected. Two hours after microinjection, cells were fixed 
and immunostained with anti-TEV and anti-HA antibodies. 
As shown in Figure 3C, the anti-TEV antibodies marked cer-
tain structures and primarily colocalized with HA, suggest-
ing that the anti-TEV antibodies recognized in situ cleaved 
proteins. Protein cleavage could not be observed in shorter 
time points (20 minutes incubation). This could be because 
of the lower concentration of anti-TEV antibodies in the 
antisera used. Therefore, affinity purification of the anti-TEV 
antibodies may be needed to achieve the high concentrations 
required for the detection of cleaved proteins at earlier time 
points. Importantly, microinjection of the TEV protease and 
dextran did not affect anti-TEV reactivity.
We noticed that in situ cleaved p115 localized to the 
Golgi within the time observed (Figure 3), unlike C-terminal 
TEV-cleaved ENLYFQ-bearing p115 (Figure 2). The differ-
ence in the localization of these two proteins may be because 
Figure 3 Detection of in-situ protein cleavage by anti-TEV antibodies. HeLa cells stably expressing the internal TEV-modified p115 with N-terminal HA tag were microinjected 
with the TEV protease and injection marker (blue). After 2 hours incubation, cells were fixed and immunostained with anti-TEV (panel C, red in panels A and B) and anti-HA 
(panel D, green in panels A and B) antibodies. The merged images are shown in A and B. images B–D represent a 3.5-fold magnification of the boxed area in A. Bar, 20 µm.
Abbreviations: EnLYFQG, Glu-Asn-Leu-Tyr-Phe-Gln-Gly; HA, hemagglutinin; TEV, tobacco etch virus.





the in situ cleaved p115 had bound to the Golgi apparatus 
before the cleavage, and ENLYFQ generated by the cuts may 
not have interfered with the pre-existing interactions.
Finally, to demonstrate the broad applications of this 
method, in vitro and in situ protein cleavage were performed 
using HeLa cells transiently expressing the internal TEV-
modified golgin 84, another Golgi-related protein. The TEV-
modified golgin 84 was immunoisolated via its N-terminal 
GFP-tag by IP with anti-GFP-agarose as described above. 
Immunoreactive complexes were treated with or without 
the TEV protease, and analyzed by Western blotting with 
anti-TEV (Figure 4A, left panel) and anti-GFP (Figure 4A, 
Figure 4 (A) Detection of in vitro cleavage of internal TEV-modified golgin 84. HeLa cells transiently expressing the TEV-modified golgin 84 with N-terminal GFP tag were used. 
GFP-tagged modified golgin 84 was immunoprecipitated with anti-GFP-agarose from cell lysates, and immunoreactive complexes were treated with or without the TEV protease 
and analyzed by Western blotting with anti-TEV (left panel) and anti-GFP (right panel, to detect the N-termini) antibodies. The anti-TEV antibodies specifically recognized the 
cleaved protein but not the full-length protein. (B–F) Detection of in-situ protein cleavage by anti-TEV antibodies. HeLa cells transiently expressing the internal TEV-modified 
golgin with N-terminal GFP tag were microinjected with the TEV protease and injection marker. After 2 hours incubation, cells were fixed and stained for anti-GM130 (panel D, 
red in panels B and C), anti-TEV (not shown) antibodies, and injection marker (blue, nuclei). Images C–F represent a 5-fold magnification of the boxed area in B. Bar, 20 µm.
Abbreviations: EnLYFQG, Glu-Asn-Leu-Tyr-Phe-Gln-Gly; GFP, green fluorescent protein; TEV, tobacco etch virus.
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right panel) antibodies. The anti-TEV antibodies specifically 
recognized the cleaved protein but not the full-length golgin 
(Figure 4A, left panel). Moreover, in situ protein cleavage was 
performed as described above. As shown in Figures 4B–4F, 
the majority of GFP signal in the protease-injected cells 
appeared to localize to the nuclei, and the rest appeared to 
be very slightly, if any, colocalized with GM130, a Golgi 
marker. Any specific labeling of anti-TEV antibodies was not 
observed, suggesting that the in situ cleaved  golgin-84 may 
have defused and been degraded. Golgin-84 has a Golgi 
localization signal at its C-terminus.20 Cleaving the N-ter-
minal part off this domain can cause a change of localization 
and degradation. For some reason, GFP signals in enzyme-
injected cells appeared in their nuclei.
The TEV antibodies could be used for the kinetic analyses 
of receptor-mediated endocytosis or signaling. This can be 
achieved by introducing a TEV cleavage site in a receptor 
of interest, subsequent to which this TEV-receptor construct 
could be used to transfect cells, allowing for the inactivation of 
the receptor at the cell surface via the TEV protease cleavage. 
The inactivated/cleaved receptor could then be detected using 
fluorescently labeled anti-TEV antibodies. Furthermore, if 
both the TEV protease and labeled anti-TEV antibodies are 
added to a cell-culture media, the fluorescence of the surface-
bound antibodies could be monitored by live imaging.
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